Allarity Therapeutics Inc. has updated its prospectus supplement, initially filed on November 29, 2023, with a new supplement dated May 9, 2024. This latest filing amends the previous prospectus supplement from March 19, 2024, and relates to the company's At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC. The amendment follows an increase in Allarity Therapeutics' public float above $75 million as of May 2, 2024, which removes the previous sales limitation under Form S-3. Consequently, the company has revised the Sales Agreement to increase the total offering of common stock to $22 million, inclusive of the $19,633,424 in gross proceeds already raised through the sale of 14,982,765 shares prior to the amendment. The company cautions investors about the high degree of risk involved in investing in its common stock, as detailed in the risk factors section of the prospectus supplement dated March 19, 2024, and other referenced documents.

Allarity Therapeutics Inc. has updated its prospectus supplement, initially filed on November 29, 2023, with a new supplement dated May 9, 2024. This latest filing amends the previous prospectus supplement from March 19, 2024, and relates to the company's At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC. The amendment follows an increase in Allarity Therapeutics' public float above $75 million as of May 2, 2024, which removes the previous sales limitation under Form S-3. Consequently, the company has revised the Sales Agreement to increase the total offering of common stock to $22 million, inclusive of the $19,633,424 in gross proceeds already raised through the sale of 14,982,765 shares prior to the amendment. The company cautions investors about the high degree of risk involved in investing in its common stock, as detailed in the risk factors section of the prospectus supplement dated March 19, 2024, and other referenced documents.